KEGG   DRUG: ToralizumabHelp
Entry
D06193                      Drug                                   

Name
Toralizumab (USAN/INN)
Efficacy
Antineoplastic, Anti-CD154 antibody
Comment
Monoclonal antibody
Treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantation such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies (such as CLL/small lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma, relapsed/refractory Hodgkin's disease)
Target
TNFSF5 (CD154) [HSA:959] [KO:K03161]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04064  NF-kappa B signaling pathway
hsa04660  T cell receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNFSF5 (CD154)
     D06193  Toralizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 252662-47-8
PubChem: 47207851
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system